Merck

Merck predicts unstoppable growth with KEYTRUDA and WINREVAIR hitting record hihs

Wane_Investment_House

Not Invested

Community Contributor

Published

10 Jul 25

Updated

14 Dec 25

Views

159

n/a

Wane_Investment_House's Fair Value

n/a

2.7%

0.4%

2.7%

0.4%

You can edit this narrative until Dec 15 12:15 PM. Then, changes will post as Updates.

Author's Valuation

US$100.350.3% overvalued

Wane_Investment_House's Fair Value

Narrative

Updates1

Shared on 14 Dec 25

Fair value Increased 36%

based on Q3 result

Wane_Investment_House'sFair Value

US$100.35

0.3% overvalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

3.58%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$23.79b

Earnings '30

13.08x

PE Ratio '30

US$311.12b

Market Cap '30

US$311.12b

Market Cap '30

2.27b

No. shares '30

US$136.86

Share Price '30

US$136.86 Share Price '30

Discounted to 2025 @ 6.40% p.a.

US$100.35

Fair Value '25